Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

NCT03791918 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: PD-1 antibody
PROCEDURE: TACE
DRUG: TACE Drug Protocol

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]